|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 59.08 USD | +0.22% |
|
-2.01% | +9.53% |
| Mar. 13 | Health Rounds: Eliquis proves safer than Xarelto for patients with deep blood clots | RE |
| Mar. 10 | BioNTech founders plan exit to set up new venture, shares slump | RE |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 5.39 | 5.99 | 5.63 | 6.55 | 10.29 | |||||
Return on Total Capital | 7.17 | 8.04 | 7.56 | 8.87 | 14.1 | |||||
Return On Equity % | 18.99 | 18.91 | 26.53 | -38.95 | 40.44 | |||||
Return on Common Equity | 18.96 | 18.88 | 26.53 | -39.1 | 40.53 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 79.87 | 78.81 | 76.63 | 75.26 | 72.62 | |||||
SG&A Margin | 16.54 | 16.69 | 17.06 | 16.28 | 14.84 | |||||
EBITDA Margin % | 44.37 | 43.68 | 40.93 | 40.18 | 39.66 | |||||
EBITA Margin % | 43.16 | 42.42 | 39.66 | 38.99 | 38.47 | |||||
EBIT Margin % | 21.17 | 21.4 | 19.22 | 20.36 | 31.21 | |||||
Income From Continuing Operations Margin % | 15.12 | 13.75 | 17.86 | -18.49 | 14.64 | |||||
Net Income Margin % | 15.08 | 13.71 | 17.83 | -18.53 | 14.64 | |||||
Net Avail. For Common Margin % | 15.08 | 13.71 | 17.83 | -18.53 | 14.64 | |||||
Normalized Net Income Margin | 14.07 | 14.45 | 14.05 | 12.79 | 20.74 | |||||
Levered Free Cash Flow Margin | 29.26 | 29.97 | 30.62 | 34.97 | 23.13 | |||||
Unlevered Free Cash Flow Margin | 31.01 | 31.53 | 32.23 | 37.5 | 25.58 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.41 | 0.45 | 0.47 | 0.51 | 0.53 | |||||
Fixed Assets Turnover | 6.77 | 6.39 | 5.8 | 5.89 | 5.51 | |||||
Receivables Turnover (Average Receivables) | 5.02 | 4.59 | 4.14 | 4.3 | 4.24 | |||||
Inventory Turnover (Average Inventory) | 4.48 | 4.41 | 4.21 | 4.58 | 5.03 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.52 | 1.25 | 1.43 | 1.25 | 1.26 | |||||
Quick Ratio | 1.36 | 1.06 | 1.24 | 1.06 | 1.08 | |||||
Operating Cash Flow to Current Liabilities | 0.74 | 0.6 | 0.62 | 0.64 | 0.6 | |||||
Days Sales Outstanding (Average Receivables) | 72.73 | 79.55 | 88.1 | 85.13 | 86.1 | |||||
Days Outstanding Inventory (Average Inventory) | 81.49 | 82.73 | 86.77 | 79.93 | 72.58 | |||||
Average Days Payable Outstanding | 110.42 | 109.03 | 106.04 | 106.01 | 98.28 | |||||
Cash Conversion Cycle (Average Days) | 43.79 | 53.25 | 68.84 | 59.05 | 60.4 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 126.63 | 131.18 | 140.82 | 312.65 | 254.98 | |||||
Total Debt / Total Capital | 55.88 | 56.74 | 58.48 | 75.77 | 71.83 | |||||
LT Debt/Equity | 112.42 | 117.04 | 129.69 | 299.06 | 241.67 | |||||
Long-Term Debt / Total Capital | 49.61 | 50.63 | 53.85 | 72.47 | 68.08 | |||||
Total Liabilities / Total Assets | 67.06 | 67.86 | 69.02 | 82.3 | 79.45 | |||||
EBIT / Interest Expense | 7.6 | 8.57 | 7.45 | 5.02 | 7.95 | |||||
EBITDA / Interest Expense | 16.14 | 17.74 | 16.21 | 10.09 | 10.28 | |||||
(EBITDA - Capex) / Interest Expense | 15.39 | 16.77 | 15.17 | 9.45 | 9.59 | |||||
Total Debt / EBITDA | 2.19 | 2 | 2.21 | 2.59 | 2.43 | |||||
Net Debt / EBITDA | 1.36 | 1.54 | 1.53 | 2.03 | 1.86 | |||||
Total Debt / (EBITDA - Capex) | 2.29 | 2.11 | 2.36 | 2.77 | 2.6 | |||||
Net Debt / (EBITDA - Capex) | 1.43 | 1.63 | 1.64 | 2.16 | 1.99 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 9.09 | -0.49 | -2.5 | 7.32 | -0.22 | |||||
Gross Profit, 1 Yr. Growth % | 8.82 | -1.81 | -5.2 | 5.4 | -3.72 | |||||
EBITDA, 1 Yr. Growth % | 13.17 | -2.97 | -8.64 | 5.36 | -1.5 | |||||
EBITA, 1 Yr. Growth % | 13.43 | -3.18 | -8.83 | 5.5 | -1.56 | |||||
EBIT, 1 Yr. Growth % | 26.72 | -1.42 | -12.43 | 13.65 | 52.96 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -177.98 | -9.54 | 26.71 | -211.11 | -178.99 | |||||
Net Income, 1 Yr. Growth % | -177.58 | -9.54 | 26.84 | -211.5 | -178.83 | |||||
Normalized Net Income, 1 Yr. Growth % | 29.9 | -0.2 | -5.23 | -2.68 | 61.8 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -178.15 | -5.45 | 30.85 | -214.36 | -178.38 | |||||
Accounts Receivable, 1 Yr. Growth % | 11.14 | 6.78 | 9.11 | -1.81 | 4.26 | |||||
Inventory, 1 Yr. Growth % | 1.01 | 11.65 | 13.81 | -3.94 | 5.2 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 3.31 | 7.28 | 7.5 | 4.03 | 9.15 | |||||
Total Assets, 1 Yr. Growth % | -7.74 | -11.43 | -1.72 | -2.69 | -2.77 | |||||
Tangible Book Value, 1 Yr. Growth % | -24.7 | -4.19 | -27.5 | 52.52 | -21.98 | |||||
Common Equity, 1 Yr. Growth % | -4.96 | -13.59 | -5.25 | -44.5 | 13.09 | |||||
Cash From Operations, 1 Yr. Growth % | 15.34 | -19.38 | 6.08 | 9.6 | -6.81 | |||||
Capital Expenditures, 1 Yr. Growth % | 29.22 | 14.9 | 8.14 | 3.23 | 5.05 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -17.28 | 0.99 | -0.16 | 22.57 | -34 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -16.74 | 0.34 | -0.34 | 24.87 | -31.93 | |||||
Dividend Per Share, 1 Yr. Growth % | 9.24 | 8.96 | 5.48 | 4.76 | 2.89 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 33.2 | 4.19 | -1.5 | 2.29 | 3.48 | |||||
Gross Profit, 2 Yr. CAGR % | 42.49 | 8.78 | -2.72 | 0.46 | 0.9 | |||||
EBITDA, 2 Yr. CAGR % | 62.45 | 20.76 | -2.38 | -0.04 | 2.67 | |||||
EBITA, 2 Yr. CAGR % | 64.75 | 21.37 | -2.48 | -0.02 | 2.74 | |||||
EBIT, 2 Yr. CAGR % | 27.13 | 70.68 | 0.46 | 3.71 | 34.08 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 42.38 | -16.01 | 7.06 | 18.65 | -6.32 | |||||
Net Income, 2 Yr. CAGR % | 42.61 | -16.22 | 7.12 | 18.92 | -6.24 | |||||
Normalized Net Income, 2 Yr. CAGR % | 21.4 | 69.35 | 4.59 | -0.31 | 27.29 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 24.59 | -14.04 | 11.23 | 22.33 | -5.32 | |||||
Accounts Receivable, 2 Yr. CAGR % | 12.52 | 8.94 | 7.94 | 3.51 | 1.18 | |||||
Inventory, 2 Yr. CAGR % | -30.14 | 6.2 | 12.72 | 4.56 | 0.52 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 0.09 | 5.27 | 7.39 | 5.75 | 6.56 | |||||
Total Assets, 2 Yr. CAGR % | -8.28 | -9.6 | -6.7 | -2.2 | -2.73 | |||||
Tangible Book Value, 2 Yr. CAGR % | -11.86 | -15.07 | -16.66 | 5.15 | 9.08 | |||||
Common Equity, 2 Yr. CAGR % | -16.53 | -9.38 | -9.52 | -27.48 | -20.77 | |||||
Cash From Operations, 2 Yr. CAGR % | 40.5 | -3.57 | -7.52 | 7.82 | 1.06 | |||||
Capital Expenditures, 2 Yr. CAGR % | 7.88 | 21.85 | 11.47 | 5.65 | 4.13 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 58.07 | 0.54 | 3.81 | 12.52 | -9.47 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 54.9 | 0.02 | 3.27 | 13.37 | -7.23 | |||||
Dividend Per Share, 2 Yr. CAGR % | 9.38 | 9.1 | 7.2 | 5.12 | 3.82 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 27.16 | 20.86 | 1.91 | 1.36 | 1.45 | |||||
Gross Profit, 3 Yr. CAGR % | 31.88 | 25.86 | 3.9 | -0.09 | -0.95 | |||||
EBITDA, 3 Yr. CAGR % | 51.93 | 37.25 | 10.04 | 0.13 | -0.53 | |||||
EBITA, 3 Yr. CAGR % | 54.06 | 38.45 | 10.33 | 0.11 | -0.54 | |||||
EBIT, 3 Yr. CAGR % | 23 | 17.58 | 36.64 | 4.68 | 18.05 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 12.34 | 22.4 | -3.67 | 8.4 | 3.6 | |||||
Net Income, 3 Yr. CAGR % | 12.44 | 22.53 | -3.8 | 8.56 | 3.69 | |||||
Normalized Net Income, 3 Yr. CAGR % | 16.69 | 14.63 | 39.55 | 2.25 | 17.16 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 1.2 | 13.64 | -1.12 | 12.26 | 5.46 | |||||
Accounts Receivable, 3 Yr. CAGR % | 19.19 | 10.58 | 9 | 4.59 | 3.76 | |||||
Inventory, 3 Yr. CAGR % | 20.58 | -18.32 | 8.68 | 6.87 | 4.77 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 11.5 | 2.43 | 6.01 | 6.26 | 6.87 | |||||
Total Assets, 3 Yr. CAGR % | 46.19 | -9.34 | -7.05 | -5.38 | -2.39 | |||||
Tangible Book Value, 3 Yr. CAGR % | 61.73 | -9.37 | -19.43 | 1.94 | -4.8 | |||||
Common Equity, 3 Yr. CAGR % | 36.83 | -15.56 | -8.02 | -23.12 | -15.9 | |||||
Cash From Operations, 3 Yr. CAGR % | 31.88 | 16.75 | -0.46 | -2.14 | 2.71 | |||||
Capital Expenditures, 3 Yr. CAGR % | 0.77 | 10.17 | 17.1 | 8.65 | 5.45 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 75.21 | 36.56 | 0.23 | 9.72 | -5.81 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 76.43 | 34.41 | -0.1 | 10.02 | -4.36 | |||||
Dividend Per Share, 3 Yr. CAGR % | 7.68 | 9.24 | 7.88 | 6.38 | 4.37 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 19.01 | 17.31 | 14.81 | 13.06 | 2.54 | |||||
Gross Profit, 5 Yr. CAGR % | 20.67 | 19.53 | 16.38 | 14.78 | 2.63 | |||||
EBITDA, 5 Yr. CAGR % | 29.23 | 34.6 | 25.71 | 20 | 6.7 | |||||
EBITA, 5 Yr. CAGR % | 30.13 | 36.25 | 26.66 | 20.62 | 6.88 | |||||
EBIT, 5 Yr. CAGR % | 13.62 | 19.94 | 10.39 | 10.1 | 34.7 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 9.25 | 45.44 | 10.2 | 20.89 | -4.74 | |||||
Net Income, 5 Yr. CAGR % | 9.43 | 44.42 | 10.28 | 21.08 | -4.79 | |||||
Normalized Net Income, 5 Yr. CAGR % | 11.23 | 14.45 | 9 | 6.88 | 33.85 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 3.32 | 37.06 | 5.1 | 17.04 | -2.82 | |||||
Accounts Receivable, 5 Yr. CAGR % | 14.63 | 13.12 | 14.55 | 7.69 | 5.8 | |||||
Inventory, 5 Yr. CAGR % | 11.04 | 14.94 | 17.37 | -9.84 | 5.34 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 6.95 | 8.37 | 9.84 | 3.75 | 6.23 | |||||
Total Assets, 5 Yr. CAGR % | 26.53 | 23.61 | 22.16 | -6.55 | -5.34 | |||||
Tangible Book Value, 5 Yr. CAGR % | 27.89 | 47.89 | 24.06 | -3.82 | -9.05 | |||||
Common Equity, 5 Yr. CAGR % | 17.31 | 21.48 | 15.97 | -20.55 | -13.35 | |||||
Cash From Operations, 5 Yr. CAGR % | 39.59 | 19.89 | 14.42 | 13.09 | 0.15 | |||||
Capital Expenditures, 5 Yr. CAGR % | -4.35 | 1.17 | 4.92 | 8.34 | 11.73 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 57.26 | 45.37 | 40.42 | 25.46 | -4.02 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 56.83 | 45.22 | 40.83 | 24.75 | -3.26 | |||||
Dividend Per Share, 5 Yr. CAGR % | 5.61 | 6.88 | 7.49 | 7.57 | 6.24 |
- Stock Market
- Equities
- BMY Stock
- Financials Bristol-Myers Squibb Company
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















